Institutional Fundamental Valuation, Quality Score & Balance Sheet Integrity
Fortis Healthcare Limited
Stanford Piotroski 9-Point Financial Health Summary
Comprehensive audit of Profitability, Leverage, Liquidity, and Operating Efficiency
Sector Peer Group Comparison (Healthcare & Pharma)
| Ticker | Company | Price | P/E | ROE | Quality Score |
|---|---|---|---|---|---|
| FORTIS (Target) | Fortis Healthcare Limited | ₹764.00 | 26.1x | 18.5% | 85/100 |
| DIVISLAB | Divi's Laboratories Limited | ₹11442.00 | 24.3x | 17.6% | 85/100 |
| LAURUSLABS | Laurus Labs Limited | ₹2424.00 | 27.0x | 19.0% | 85/100 |
| PINELABS | Pine Labs Limited | ₹176.44 | 25.6x | 18.3% | 85/100 |
| PARASHLTH | Paras Healthcare Limited | ₹936.30 | 37.3x | 24.1% | 85/100 |
| NATCOPHARM | Natco Pharma Limited | ₹810.45 | 25.4x | 18.2% | 85/100 |
Educational & Research Disclosure: InvestResearch India is an independent analytical research platform. We are NOT a SEBI-registered Investment Adviser (IA) or Research Analyst (RA). This equity factsheet is algorithmically generated based on audited quarterly/annual regulatory filings made to the National Stock Exchange of India (NSE) and BSE Limited. It does not constitute investment advice, buy/sell recommendation, or price target projection.
Equity securities involve significant market and operational risks including loss of capital. Investors must conduct independent due diligence or consult a qualified SEBI-registered professional before making investment decisions.